256 related articles for article (PubMed ID: 17631950)
1. A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia.
Roman LD; Wilczynski S; Muderspach LI; Burnett AF; O'Meara A; Brinkman JA; Kast WM; Facio G; Felix JC; Aldana M; Weber JS
Gynecol Oncol; 2007 Sep; 106(3):558-66. PubMed ID: 17631950
[TBL] [Abstract][Full Text] [Related]
2. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia.
Hallez S; Simon P; Maudoux F; Doyen J; Noël JC; Beliard A; Capelle X; Buxant F; Fayt I; Lagrost AC; Hubert P; Gerday C; Burny A; Boniver J; Foidart JM; Delvenne P; Jacobs N
Cancer Immunol Immunother; 2004 Jul; 53(7):642-50. PubMed ID: 14985860
[TBL] [Abstract][Full Text] [Related]
3. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive.
Muderspach L; Wilczynski S; Roman L; Bade L; Felix J; Small LA; Kast WM; Fascio G; Marty V; Weber J
Clin Cancer Res; 2000 Sep; 6(9):3406-16. PubMed ID: 10999722
[TBL] [Abstract][Full Text] [Related]
4. Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III.
Einstein MH; Kadish AS; Burk RD; Kim MY; Wadler S; Streicher H; Goldberg GL; Runowicz CD
Gynecol Oncol; 2007 Sep; 106(3):453-60. PubMed ID: 17586030
[TBL] [Abstract][Full Text] [Related]
5. Serological response to an HPV16 E7 based therapeutic vaccine in women with high-grade cervical dysplasia.
Van Doorslaer K; Reimers LL; Studentsov YY; Einstein MH; Burk RD
Gynecol Oncol; 2010 Feb; 116(2):208-12. PubMed ID: 19555999
[TBL] [Abstract][Full Text] [Related]
6. CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer.
Daniel D; Chiu C; Giraudo E; Inoue M; Mizzen LA; Chu NR; Hanahan D
Cancer Res; 2005 Mar; 65(5):2018-25. PubMed ID: 15753402
[TBL] [Abstract][Full Text] [Related]
7. Vaccination trial with HPV16 L1E7 chimeric virus-like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3).
Kaufmann AM; Nieland JD; Jochmus I; Baur S; Friese K; Gabelsberger J; Gieseking F; Gissmann L; Glasschröder B; Grubert T; Hillemanns P; Höpfl R; Ikenberg H; Schwarz J; Karrasch M; Knoll A; Küppers V; Lechmann M; Lelle RJ; Meissner H; Müller RT; Pawlita M; Petry KU; Pilch H; Walek E; Schneider A
Int J Cancer; 2007 Dec; 121(12):2794-800. PubMed ID: 17721997
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of human papilloma virus type 16 E7 specific T cell responses by local invasive procedures in patients with (pre)malignant cervical neoplasia.
Visser J; van Baarle D; Hoogeboom BN; Reesink N; Klip H; Schuuring E; Nijhuis E; Pawlita M; Bungener L; de Vries-Idema J; Nijman H; Miedema F; Daemen T; van der Zee A
Int J Cancer; 2006 May; 118(10):2529-37. PubMed ID: 16353143
[TBL] [Abstract][Full Text] [Related]
9. Small lesion size measured by colposcopy may predict absence of cervical intraepithelial neoplasia in a large loop excision of the transformation zone specimen.
Munmany M; Marimon L; Cardona M; Nonell R; Juiz M; Astudillo R; Ordi J; Torné A; Del Pino M
BJOG; 2017 Feb; 124(3):495-502. PubMed ID: 27506510
[TBL] [Abstract][Full Text] [Related]
10. T-cell response to human papillomavirus type 52 L1, E6, and E7 peptides in women with transient infection, cervical intraepithelial neoplasia, and invasive cancer.
Chan PK; Liu SJ; Cheung JL; Cheung TH; Yeo W; Chong P; Man S
J Med Virol; 2011 Jun; 83(6):1023-30. PubMed ID: 21503915
[TBL] [Abstract][Full Text] [Related]
11. Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide.
Kadish AS; Timmins P; Wang Y; Ho GY; Burk RD; Ketz J; He W; Romney SL; Johnson A; Angeletti R; Abadi M;
Cancer Epidemiol Biomarkers Prev; 2002 May; 11(5):483-8. PubMed ID: 12010863
[TBL] [Abstract][Full Text] [Related]
12. T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection.
de Gruijl TD; Bontkes HJ; Stukart MJ; Walboomers JM; Remmink AJ; Verheijen RH; Helmerhorst TJ; Meijer CJ; Scheper RJ
J Gen Virol; 1996 Sep; 77 ( Pt 9)():2183-91. PubMed ID: 8811018
[TBL] [Abstract][Full Text] [Related]
13. High-risk cervical epithelial neoplasia grade 1 treated by loop electrosurgical excision: follow-up and value of HPV testing.
Alonso I; Torné A; Puig-Tintoré LM; Esteve R; Quinto L; Garcia S; Campo E; Pahisa J; Ordi J
Am J Obstet Gynecol; 2007 Oct; 197(4):359.e1-6. PubMed ID: 17714678
[TBL] [Abstract][Full Text] [Related]
14. A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions.
de Vos van Steenwijk PJ; Ramwadhdoebe TH; Löwik MJ; van der Minne CE; Berends-van der Meer DM; Fathers LM; Valentijn AR; Oostendorp J; Fleuren GJ; Hellebrekers BW; Welters MJ; van Poelgeest MI; Melief CJ; Kenter GG; van der Burg SH
Cancer Immunol Immunother; 2012 Sep; 61(9):1485-92. PubMed ID: 22684521
[TBL] [Abstract][Full Text] [Related]
15. Inverse correlation of cellular immune responses specific to synthetic peptides from the E6 and E7 oncoproteins of HPV-16 with recurrence of cervical intraepithelial neoplasia in a cross-sectional study.
Sarkar AK; Tortolero-Luna G; Follen M; Sastry KJ
Gynecol Oncol; 2005 Dec; 99(3 Suppl 1):S251-61. PubMed ID: 16188303
[TBL] [Abstract][Full Text] [Related]
16. A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals.
Palefsky JM; Berry JM; Jay N; Krogstad M; Da Costa M; Darragh TM; Lee JY
AIDS; 2006 May; 20(8):1151-5. PubMed ID: 16691066
[TBL] [Abstract][Full Text] [Related]
17. Differential T helper cell responses to human papillomavirus type 16 E7 related to viral clearance or persistence in patients with cervical neoplasia: a longitudinal study.
de Gruijl TD; Bontkes HJ; Walboomers JM; Stukart MJ; Doekhie FS; Remmink AJ; Helmerhorst TJ; Verheijen RH; Duggan-Keen MF; Stern PL; Meijer CJ; Scheper RJ
Cancer Res; 1998 Apr; 58(8):1700-6. PubMed ID: 9563486
[TBL] [Abstract][Full Text] [Related]
18. Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia.
Kadish AS; Ho GY; Burk RD; Wang Y; Romney SL; Ledwidge R; Angeletti RH
J Natl Cancer Inst; 1997 Sep; 89(17):1285-93. PubMed ID: 9293919
[TBL] [Abstract][Full Text] [Related]
19. Profiling of serum antibodies against human papillomavirus antigens in Korean women with cervical intraepithelial neoplasia and cervical cancer.
Jin Y; Choi JW; Kim HJ; Eddouzi J; Kim SC; Ju W; Kim YH; Kim HJ
Cancer Med; 2018 Nov; 7(11):5655-5664. PubMed ID: 30353680
[TBL] [Abstract][Full Text] [Related]
20. Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia.
Visser J; Nijman HW; Hoogenboom BN; Jager P; van Baarle D; Schuuring E; Abdulahad W; Miedema F; van der Zee AG; Daemen T
Clin Exp Immunol; 2007 Nov; 150(2):199-209. PubMed ID: 17937675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
